Inovio Pharmaceuticals (INO) Stock Continues Flying

Inovio Pharmaceuticals INO Stock News

Inovio Pharmaceuticals Inc (NASDAQ: INO) has been on a dramatic run for the top. Since the company announced that it was accelerating its coronavirus vaccine timeline six days ago, the stock has climbed from around $4.50 per share to nearly $18 per share in the premarket this morning.The gains are continuing this morning to the tune of more than 26%. So, what’s the deal?

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

INO Stock Climbs On Coronavirus Vaccine Timeline

As mentioned above, the catalyst that started the recent gains in Innovio Pharmaceuticals has to do with the timeline of the company’s coronavirus vaccine development. Here’s a quick run down of the timeline:

On December 31, 2019, INO said that its scientists learned about the Wuhan coronavirus, or COVID-19. By January 10, 2020, the company designed a DNA vaccine known as INO-4800 within three hours of receiving the genetic sequence of the coronavirus from Chinese researchers.

Starting on January 10th and running through January 23rd, the company pushed for manufacturing of the coronavirus vaccine candidate to begin preclinical testing. On January 23rd, the company received a grant of up to $9 million from the CEPI to fund ongoing preclinical trials and initial development of INO-4800.

Starting on January 23rd, the company saw immune responses generated in animal models as preclinical testing continued. From January 23rd through February 29th, the company continued this preclinical testing and designed human clinical trials.

In March, INO said that preclinical studies will continue. Moreover, the human clinical trial design will be finalized with 3,000 human trial doses prepared for trials in the United States, China and South Korea. The company has also already developed large-scale manufacturing plans.

In April, the company said it expects for human trials to begin in 30 healthy volunteers. These trials will begin in China and push to South Korea shortly therafter. The company expects for the final results from the trial to be available in the fall of this year. Moreover, by the end of the year, the company intends on having 1 million doses of the vaccine produced for further trials and emergency use.

In a statement, Dr. J. Joseph Kim, President and CEO at INO, had the following to offer:

Inovio is the leader in coronavirus vaccine development and the only company with a Phase 2 vaccine for a related coronavirus that causes Middle East Respiratory Syndrome (MERS). Using our modern DNA medicines platform, we designed our DNA vaccine INO-4800 in three hours after the publication of the genetic sequence of the novel coronavirus that causes COVID-19.

We immediately began preclinical testing and small-scale manufacture and have already shared robust preclinical data with our public and private partners. We plan to begin human clinical trials in the U.S. in April and soon thereafter in China and South Korea, where the outbreak is impacting the most people. We plan on delivering one million doses by year end with existing resources and capacity. However, we will need additional resources to scale up to make enough doses to help protect Americans from COVID-19 as well as to lead global efforts to curtail this virus.

There Are Several Key Advantages At Play Here

If you follow coronavirus stocks, you know that Innovio Pharmaceuticals is only one of a long list of companies in a race to develop a vaccine. So, why is it that investors are so excited here? Well, it has to do with several key advantages that the company has.

First and foremost, INO isn’t just developing a vaccine. The company is developing a DNA-based vaccine that is laser targeted to fight against the onset of the Wuhan coronavirus. This unique approach to developing a vaccine is showing incredibly promising results in animal models and is likely to do the same in humans, which brings us to our next key advantage.

While there are quite a few competitors racing toward the same goal, there are very few that have actually made any real progress. In fact, INO is one of less than 5 companies that I know of that are either already working on trials in animals or humans, or have them planned already.

Considering this, there is indeed competition on the playing field, but if this were a horse race, INO would be lapping the vast majority of its competitors. So, there’s good reason for all of the investor excitement here.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story!

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.